The Zyprexa Chronicles: US Sales Down 5 Percent

Eli Lilly's first quarter sales and earnings were announced today. Worldwide sales of Zyprexa were up 1 percent to $1.1 billion, but US sales of the controversial antipsychotic were down 5 percent "because of competition from newer products and worries over weight gain, which can increase risk of diabetes," according to Forbes.

Sales of the anti-depressant Cymbalta rose 37 percent to $605 million.